| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 77, 664-669, Copyright © 1993 by Endocrine Society
ARTICLES |
HN Rosen, AC Moses, C Gundberg, VT Kung, SM Seyedin, T Chen, M Holick and SL Greenspan
Charles A. Dana Research Institute, Harvard-Thorndike Laboratory, Beth Israel Hospital, Boston, Massachusetts 02215.
Bisphosphonates have been shown to decrease bone turnover in a variety of high turnover states. We postulated that pamidronate (APD), a bisphosphonate, could prevent the increased bone turnover caused by thyroid hormone excess. Twenty-two male subjects were randomized to receive either placebo (group 1) or APD (30 mg, iv, daily for 2 days; group 2). Subsequently, all subjects received T3 (50 micrograms, twice daily, for 8 days). Biochemical indices of bone turnover were measured in blood and urine at baseline, after treatment with APD/placebo, and after treatment with T3. The urinary calcium/creatinine ratio (Uca/cr) fell significantly after treatment with APD, but not after treatment with placebo (group 1, 0.131 +/- 0.021; group 2, 0.040 +/- 0.013 mmol Ca/mmol Cr; P < 0.002). After treatment with T3, Uca/cr rose significantly in group 1, but not in group 2 (group 1, 0.275 +/- 0.042; group 2, 0.065 +/- 0.025 mmol Ca/mmol Cr; P < 0.05). Thus, APD prevented the rise in Uca/cr caused by treatment with T3. Similar results were obtained with urinary hydroxyproline and urinary pyridinoline cross-links. We conclude that 8 days of mild thyroid hormone excess in normal men increases bone turnover, and prior administration of APD prevents thyroid hormone-induced increases in bone resorption. APD may be useful in the prevention of thyroid hormone- induced osteopenia.
This article has been cited by other articles:
 |
|
 |
|
  B. Biondi, E. A. Palmieri, M. Klain, M. Schlumberger, S. Filetti, and G. Lombardi Subclinical hyperthyroidism: clinical features and treatment options Eur. J. Endocrinol., January 1, 2005; 152(1): 1 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A C Al-Abadi Subclinical thyrotoxicosis Postgrad. Med. J., January 1, 2001; 77(903): 29 - 29. [Full Text]
|
|
|
|
 |
|
 J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Greenspan and F. S. Greenspan The Effect of Thyroid Hormone on Skeletal Integrity Ann Intern Med, May 4, 1999; 130(9): 750 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. N. Rosen, A. C. Moses, J. Garber, D. S. Ross, S. L. Lee, L. Ferguson, V. Chen, K. Lee, and S. L. Greenspan Randomized Trial of Pamidronate in Patients with Thyroid Cancer: Bone Density Is Not Reduced by Suppressive Doses of Thyroxine, But Is Increased by Cyclic Intravenous Pamidronate J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2324 - 2330. [Abstract] [Full Text]
|
|
|
|
|
|
C. S. Mantzoros, H. N. Rosen, S. L. Greenspan, J. S. Flier, and A. C. Moses Short-Term Hyperthyroidism Has No Effect on Leptin Levels in Man J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 497 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wartofsky Thyroid Hormones and Osteoporosis-Reply Arch Intern Med, February 12, 1996; 156(3): 341 - 341. [Abstract] [PDF]
|
|
|
|
|
|
L. Wartofsky Levothyroxine Therapy and Osteoporosis: An End to the Controversy? Arch Intern Med, June 12, 1995; 155(11): 1130 - 1131. [Abstract] [PDF]
|
|
|
|
 |
|
 D. S. Cooper Thyroid Hormone, Osteoporosis, and Estrogen JAMA, April 27, 1994; 271(16): 1283 - 1284. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
